.jpg "Vivi Boura, MD,PhD photo")
Chief Medical Officer
SOTIO Biotech AG, Switzerland
Vivi Boura, MD,PhD is a seasoned medical executive and clinical researcher specializing in oncology and immuno-oncology, with over two decades of experience in academic medicine and clinical development. She currently serves as Chief Medical Officer at SOTIO A.G., Basel, Switzerland (since Oct 2025), following previous roles as Deputy Chief Medical Officer and Senior Medical Director for Early Clinical Development in Oncology. In these capacities, she has driven strategic leadership for antibody–drug conjugate (ADC) programs, overseen Phase II immunotherapy trials, led pre-IND/IND regulatory submissions, and represented the company before the FDA, EMA, and PMDA.
Earlier, as Medical Director at SOTIO, Dr. Boura designed and implemented global clinical development strategies, led cross-functional medical–regulatory collaborations, and engaged extensively with key opinion leaders.
Her academic background includes over a decade as Senior Research Associate at the University of Athens, 3rd Department of Internal Medicine (Oncology Unit, Sotiria Hospital), where she participated as investigator in more than 70 Phase II–III oncology trials and conducted translational research in tumor biology and biomarkers. In parallel, she held academic appointments, teaching at the University of Athens and lecturing in postgraduate programs on thoracic malignancies.
Dr Boura earned her medical degree from the Aristotle University of Thessaloniki, School of Medicine, and a PhD in Medicine from the University of Athens, where her research focused on biomarkers in lung cancer.
She is the recipient of multiple academic scholarships, and is an active member of major international societies. Her extensive publication record includes over 40 peer-reviewed papers in lung cancer, biomarkers, and clinical oncology.
